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Abstract. During terminal differentiation of skeletal 
myoblasts, cells fuse to form postmitotic multinucleated 
myotubes that cannot reinitiate DNA synthesis. Here 
we investigated the temporal relationships among these 
events during in vitro differentiation of C2C12 myo- 
blasts. Cells expressing myogenin, a marker for the en- 
try of myoblasts into the differentiation pathway, were 
detected first during myogenesis, followed by the ap- 
pearance of mononucleated cells expressing both 
myogenin and the cell cycle inhibitor p21. Although ex- 
pression of both proteins was sustained in mitogen- 
restimulated myocytes, 5-bromodeoxyuridine incorpo- 
ration experiments in serum-starved cultures revealed 
that myogenin-positive cells remained capable of repli- 
cating DNA. In contrast, subsequent expression of p21 
in differentiating myoblasts correlated with the estab- 
lishment of the postmitotic state. Later during myogen- 
esis, postmitotic (p21-positive) mononucleated myo- 
blasts activated the expression of the muscle structural 
protein myosin heavy chain, and then fused to form 
multinucleated myotubes. Thus, despite the asynchrony 
in the commitment to differentiation, skeletal myogen- 
esis is a highly ordered process of temporally separable 
events that begins with myogenin expression, followed 
by p21 induction and cell cycle arrest, then phenotypic 
differentiation, and finally, cell fusion. 
in many cell lineages, proliferation and phenotypic 
differentiation of skeletal myoblasts are mutually 
exclusive events. Skeletal myogenesis can be in- 
duced in culture by depriving cycling myoblasts of serum, 
which then form multinucleated myotubes that  are irre- 
versibly postmitotic (20, 37). A coordinate induction of mus- 
cle-specific gene products occurs concomitantly with these 
morphological changes (2, 40). Members of the MyoD fam- 
ily of muscle-specific transcription factors (MyoD, myoge- 
nin,  Myf-5,  MRF4) are involved in these processes, and 
their ectopic expression in a variety of nonmuscle cells can 
promote myogenesis (7, 17, 38, 46). Although MyoD can 
inhibit cell cycle progression in vitro independently of dif- 
ferentiation (12, 43), the basis for the antagonism between 
cell proliferation and differentiation has remained obscure 
(28, 36). Recently, the reported induction of the cell cycle 
inhibitor p21 during myogenesis has provided insight  into 
the mechanism that might couple cell cycle arrest and myo- 
genic differentiation (21, 22, 39). The induction of p21 can 
account, at least in part, for the decrease in cyclin-depen- 
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dent  kinase  (Cdk) 1 activity in  differentiating  myocytes, 
and its ectopic expression in myoblasts is sufficient for cell 
cycle arrest in mitogen-rich medium (21). 
Although  some aspects  of muscle  differentiation  and 
cell cycle control have been elucidated, the temporal rela- 
tionships among the events that govern the transition from 
proliferative  myoblasts  to  the  terminally  differentiated 
multinucleated  myocytes  have  remained  controversial. 
Several studies have suggested that the postmitotic state is 
not acquired until myocytes fuse (8, 9, 15, 16, 19, 26, 31, 
33-35).  However,  other  studies  support  the  contention 
that cell cycle withdrawal occurs before the expression of 
contractile proteins and cell fusion (3-5, 10, 18, 23, 24, 29, 
30, 32, 42, 44, 50). Using molecular probes that were not 
available when  these  prior  studies  were performed,  we 
show here that myoblasts induce the synthesis of myoge- 
nin before the establishment of the postmitotic state. After 
myogenin expression, skeletal myogenesis proceeds through 
a highly ordered sequence of events that begins with p21 
induction  and cell cycle withdrawal, followed by the ex- 
pression of the contractile apparatus,  and finally,  cell fu- 
sion to form multinucleated myotubes. 
1. Abbreviations used in this paper: BrdU, 5-bromodeoxyuridine; Cdk, cy- 
clin-dependent kinase; MHC, myosin heavy chain. 
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Cell Culture 
C2C12  mouse skeletal myoblasts (American Type  Culture  Collection, 
RockviUe, MD) were cultured at 37°C in a humidified atmosphere con- 
taining 5% CO2. Cells were maintained at subconfluent densities in DME 
supplemented with 20% FCS (growth medium). Myogenic differentiation 
was induced by changing subconfluent (60-70%) cells to DME containing 
2% heat-inactivated horse serum (differentiation medium). 
Antibodies 
The following antibodies were used in this study: rabbit polyclonaI anti- 
bodies C-19 (anti-p21) and C-22 (anti-Cdk4) (Santa Cruz Biotech., Santa 
Cruz, CA), mouse mAb MF-20, which stains all sarcomeric myosin heavy 
chain (MHC) isoforms (1), and mouse mAb F5D, which reacts with re- 
combinant myogenin but not with MyoD, Myf-5, or MRF4 (13, 48). 
lmmunoblot Analysis 
Whole cell extracts were prepared as previously described (21). Proteins 
(40 Ixg) were separated by electrophoresis through SDS-PAGE (27)  and 
transferred by semidry blotting to Immobilon-P membranes (0.45  l~m; 
Millipore Corp., Bedford, MA). Membranes were blocked for 1 h  with 
TBST (25 mM Tris-C1, pH 8.0, 125 mM NaCI, 0.05% Tween-20) contain- 
ing 4% nonfat dry milk and then incubated for 1 h with primary antibodies 
diluted in 2% nonfat dry milk, TBST (MF-20 and F5D, 1:10; C-19,  1:50; 
C-22, 1:200). After washes with TBST, membranes were incubated for 30 
min with species-appropriate HRP-conjugated secondary antibodies (di- 
luted  1:3,500;  Amersham Corp.,  Arlington  Heights,  IL),  washed with 
TBST, and finally, washed with PBS. Visualization of the immune com- 
plexes was carried out with an enhanced chemiluminescent system (Am- 
ersham Corp.). 
Immunofluorescence Microscopy 
For immunofluorescence analysis, C2C12 cells were seeded onto sterile 
glass coverslips that had been soaked for 5-10 min in 70% ethanol/0.4% 
HCI, rinsed extensively with water, washed in 95% ethanol, and air dried. 
Myogenic differentiation was  induced  as  indicated  above.  Cells were 
washed three times with PBS before fixation and immunostaining. Unless 
otherwise specified, all manipulations were at room temperature, all dilu- 
tions of antibodies were prepared in 2% normal goat serum, 0.1% NP-40 
(in PBS), and incubations were followed by washes with 0.1% NP-40 in 
PBS. Cells were fixed for 5-10 min with cold methanol (-20°C), rehy- 
drated with PBS, blocked for 15 min in 10% normal goat serum (in PBS), 
and incubated for 1 h with primary antibody mixtures prepared for double 
immunofluorescence labeling. For p21/MHC and p21/myogenin costain- 
ing, the C-19 antipeptide rabbit polyclonal antibody was diluted 1:25 in 
MF-20 and F5D hybridoma tissue culture supernatants, respectively. For 
peptide competition, 40 i~g/ml of either p21  immunogenic peptide or an 
unrelated peptide corresponding to amino acids 282-303 of human Cdk4 
(both from Santa Cruz Biotech.) was added to the C-19/MF-20 antibody 
mixture 1-2 h  before incubation of coverslips. After extensive washes, 
cells were incubated for 45 min with biotinylated anti-rabbit IgG (dilution 
1:200; Amersham Corp.), followed by incubation for 45 min with a cock- 
tail  of streptavidin-Texas  red  (dilution  1:500; Amersham  Corp.)  and 
FITC-conjugated anti-mouse IgG (dilution 1:250; Kirkegaard and Perry 
Laboratories, Inc., Gaithersburg, MD). No cross-reactivity of the second- 
ary antibodies was observed in control experiments in which either pri- 
mary antibody was omitted (data not shown). After washes, nuclei were 
counterstained with 0.05  ixg/ml Hoechst 33258  (Boehringer Mannheim 
Biochemicals, Indianapolis, IN) for 1-2 min before mounting. 
For  5-bromodeoxyuridine  (BrdU)  incorporation  experiments, asyn- 
chronously growing C2C12 cells were changed to differentiation medium 
and labeled for the indicated times with 10 ixM BrdU (Amersham Corp.). 
After labeling, coverslips were processed for indirect immunofluorescence 
essentially as above. Briefly, cells were incubated with either C-19 (anti- 
p21) or F5D (anti-myogenin) antibodies, followed by species-appropriate 
biotinylated secondary antibodies and  streptavidin-Texas red.  Cellular 
DNA was denatured for 30 min at 37°C in 2 N HC1 and 0.5% Triton X-100. 
After extensive washes first with 0.l M sodium tetraborate, pH 8.5, and 
then with PBS, cells were stained with FfTC-conjugated anti-BrdU mAb 
(dilution 1:20; Boehringer Mannheim Biochemicals), counterstained with 
Hoechst 33258, and mounted for examination. 
Coverslips were mounted on glass slides (mounting medium for fluo- 
rescence, Kirkegaard and Perry Laboratories, Inc.). Specimens were ex- 
amined and photographed on a Diaphot microscope (Nikon Inc., Garden 
City, NY) equipped with phase-contrast and epifiuorescence optics (× 100 
lens). Pictures were recorded on Kodak Gold Plus film (Eastman Kodak 
Co., Rochester, NY). 
Results 
We  first  examined by  indirect  immunofluorescence the 
subcellular localization of p21 in C2C12 cells, a well-char- 
acterized  murine  skeletal  muscle  cell  line.  Cells  were 
stained simultaneously for p21 (red) and MHC (green), a 
marker of myogenic differentiation. Although undifferen- 
tiated myoblasts revealed a  low level of red fluorescent 
signal (Fig. 1 a), this signal was also detected in control ex- 
periments  in  which  the  anti-p21  antibody  was  omitted 
(data not shown), indicating that myoblasts are essentially 
devoid of p21. In contrast, terminally differentiated myo- 
tubes displayed a strong nuclear p21 signal (Fig. 1 b) that 
could  be  abrogated  by  preincubating  the  anti-p21/anti- 
MHC antibody mixture with the p21-immunogenic pep- 
tide, but not with an unrelated peptide (Fig. 1, c and d). In 
agreement with the results with C2C12 cells, p21 was also 
detected within the nuclei of myotubes obtained from pas- 
saged cultures of nonimmortalized diploid human skeletal 
muscle cells (data not shown). 
Myogenin Expression and Cell Cycle Withdrawal Are 
Temporally Separable Events 
The above results  demonstrate the expression of p21  in 
postmitotic myotubes, consistent with the suggested role 
of p21 in coupling cell cycle withdrawal and myogenic dif- 
ferentiation (21, 22, 39). It has been previously suggested 
that expression of myogenin, an early marker for the entry 
of myoblasts into the differentiation pathway (16, 47), only 
occurs in postmitotic myocytes (6, 38, 49). Thus, our initial 
interest was  to determine whether myogenin expression 
and  cell  cycle  withdrawal  are  separable  or  concurrent 
events. To this end, C2C12 myoblasts were induced to dif- 
ferentiate for 19 h and then examined simultaneously for 
myogenin  expression  and  BrdU  incorporation  into  na- 
scent genomic DNA.  No multinucleated myotubes were 
observed in these cultures at this time point. As shown in 
Fig.  2,  a  significant  fraction  of  myogenin  +  cells  were 
Figure 1.  Expression and subcellular localization of p21 in C2C12 myotubes. Indirect immunofluorescence of C2C12 cells stained simul- 
taneously with anti-p21 and anti-MHC antibodies. Cells were examined using a dual filter for red (p21) and green (MHC) fluorescence. 
Representative fields are shown (top, immunofluorescence; bottom, Hoechst 33258 nuclear staining). (a) Cells maintained in growth me- 
dium (myoblasts). Similar pattern was observed in control experiments in which the anti-p21 antibody was omitted (not shown). (b-d) 
Cells maintained for 3 d  in differentiation medium (myotubes). For peptide competition, the anti-p21/anti-MHC antibody mixture was 
preincubated with an excess of p21 immunogenic peptide (c) or with an unrelated peptide (d) before incubation of cells. 
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cell cycle withdrawal in differentiating myocytes. (A) C2C12 cells 
were exposed to differentiation medium (DM) for 19 h  and la- 
beled with  10  ixM BrdU  for the last 4  h  before double immu- 
nostaining for BrdU (green) and either myogenin or p21  (red). 
Open arrowheads, myogenin+/BrdU  -  or p21÷/BrdU -  cells. Solid 
arrowheads, two myogenin+/BrdU  + cells. (B) Relative frequency 
of BrdU  + nuclei among p21-positive cells (p21  +), myogenin-posi- 
tive cells (Myog+),  or cells that did not express either p21 or myo- 
genin (-). n, number of cells analyzed in each case. 
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sustained differentiation medium for 4 d and then serum-restimulated with growth medium for 20 h (A) or 16 h (B and C). (A) Cells 
were stained simultaneously for p21 and MHC and examined using a dual filter for red (p21) and green (MHC) fluorescence. A repre- 
sentative field  is shown (top, immunofluorescence; bottom, Hoechst 33258 staining),  p21 is expressed in both mononucleated MHC- 
cells (arrowheads) and syncytial MHC  ÷ myotubes. (B) Ceils were continuously labeled with 10 ixM'BrdU during serum restimulation 
and then double stained for p21 (red) and BrdU (green). (C) Frequency of BrdU- and BrdU + nuclei among mononucleated p21- and 
p21 ÷ cells, n, number of cells analyzed in each case. 
BrdU ÷ (34%, n  =  338), indicating that myoblasts express- 
ing myogenin remain capable of replicating DNA. In strik- 
ing contrast,  the great majority of p21 + cells in these dif- 
ferentiating cultures were BrdU-  (98%, n  =  455). These 
results demonstrate that expression of the cell cycle inhibi- 
tor p21,  but  not myogenin, correlates  with  the  establish- 
ment of the postmitotic state in differentiating myoblasts. 
Further indication that p21 expression reflects the post- 
mitotic state was provided by analyzing cultures of serum- 
restimulated myocytes, which cannot reinitiate DNA synthe- 
sis in response  to mitogens  (11, 24, 25, 44). We reasoned 
that,  if p21  is involved in the maintenance  of the postmi- 
totic  state,  its  expression  would  be  sustained  in  serum- 
restimulated myotubes. In this study, cells were induced to 
differentiate for 4 d, then serum restimulated for 20 h, and 
double  stained  for p21  and  MHC.  Expression  of p21  in 
these  serum-restimulated  cultures  was  detected  both  in 
mature  myotubes and  in MHC  ÷ and MHC-  mononucle- 
ated  cells  (Fig.  3 A).  In another  experiment  where  cells 
were serum starved for 2 d and serum restimulated for 20 h, 
the frequency of p21 ÷ nuclei before and after mitogen re- 
stimulation was 33% (n =  303) and 32% (n =  307), respec- 
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reversed by growth factor reexposure even in undifferenti- 
ated mononucleated myoblasts. Furthermore, p21 expres- 
sion in serum-restimulated cultures correlated with the ab- 
sence of DNA synthesis in all myotubes (data not shown) 
and in nearly all p21 ÷ mononucleated cells (98%, n  =  201; 
Fig. 3, B  and C). In contrast, p21-  (mononucleated) cells 
had entered S phase at a  high frequency under the same 
conditions (72%, n  =  228; Fig. 3, B  and C). Thus, the ex- 
pression properties of p21 in mononucleated myocytes and 
syncytial myotubes are consistent with its possible involve- 
ment in both the maintenance as well as the establishment 
of  the  postmitotic  state.  Similar  experiments  analyzing 
myogenin expression after serum restimulation were also 
performed. The frequency of myogenin  ÷ nuclei in cultures 
that were serum-starved for 1 d or serum restimulated for 
19 h  after serum starvation was 13% (n  =  1013) and 11% 
(n =  1064), respectively. The sustained expression of myo- 
genin in serum restimulated myocytes indicates that it is an 
early marker of cells that are irreversibly committed to ter- 
minal  differentiation;  however,  the  high  frequency  of 
BrdU÷/myogenin  +  cells  demonstrates  that  myogenin  is 
not a marker of the postmitotic state. 
Myogenin Expression,  Cell Cycle Withdrawal, 
Phenotypic Differentiation,  and Cell Fusion Are Highly 
Ordered Events during Skeletal Myogenesis 
The ability of myogenin  + myocytes to replicate DNA and 
the  detection  of postmitotic mononucleated MHC-  cells 
in differentiating cultures provided a  first indication  that 
myocytes might withdraw from the cell cycle after induc- 
tion  of  myogenin  but  before  phenotypic  differentiation 
and fusion. In view of the above data demonstrating that 
p21 is a marker of cell cycle withdrawal (Figs. 2 and 3), we 
examined by immunoblot analysis the timing of p21 induc- 
tion relative to myogenin and MHC expression. As shown 
in Fig. 4,  expression of myogenin preceded the induction 
of p21, which  in  turn  preceded the  expression  of MHC. 
Whereas  p21  appeared  to  reach  maximum levels  of ex- 
pression by day 2 in differentiation medium, MHC steadily 
increased up to day 4. Although Western blot analysis re- 
vealed low levels of p21 in proliferating myoblasts, no specific 
nuclear signal was detected  in  myoblasts immunostained 
for p21 (Fig. 1 a), suggesting that the immunofluorescence 
method was unable to detect the low levels of p21 protein 
that occur in myoblasts. The specificity of the p21 antibody 
used  in  the  immunoblot  analysis  was  demonstrated  in 
competition experiments with immunogenic peptide, which 
resulted in a  decreased signal. The level of expression of 
the cell cycle regulator Cdk4 did not apparently change 
Figure 4.  Time course of expression of myogenin, p21, and MHC 
during  myogenesis.  Western blot analysis  on cell extracts pre- 
pared from C2C12 cel~maintained in growth medium (GM) or 
after the  indicated  periods  of time in  differentiation  medium 
(DM). For peptide competition (a-p21 + peptide), the polyclonal 
anti-p21  antibody was preincubated with an excess of immuno- 
genic  peptide  before  probing  the  membrane.  The  molecular 
weight of protein markers is shown (kD). 
in  differentiating  cultures,  in  agreement  with  previous 
studies (41). 
The above results suggest an overall order of marker ex- 
pression during myogenesis; however, they do not rule out 
that these processes are stochastic at the level of the indi- 
vidual ceil. Thus, to investigate on a  cell-by-cell basis the 
temporal relationships  among myogenin expression,  cell 
cycle withdrawal,  phenotypic differentiation,  and cell fu- 
sion,  double immunofluorescence experiments were per- 
formed on cultures of C2C12 cells at different time points 
after serum deprivation. To determine the temporal rela- 
tionship between myogenin expression and cell cycle with- 
drawal,  cells were double stained for myogenin and  p21 
(Fig.  5  A).  Myogenin÷/p21 -  (mitotic)  cells,  as  well  as 
myogenin+/p21 ÷ (postmitotic) cells were detected in these 
cultures.  However,  myogenin-/p21 ÷  (postmitotic)  cells 
were  not  observed in  differentiating  cultures,  suggesting 
that differentiating myoblasts withdraw from the cell cycle 
after induction of myogenin. Consistent with these obser- 
vations,  the  relative  frequency of p21 ÷  cells  among the 
population of myogenin  ÷ cells increased from 58 to 82% 
at  days 1  and  2  in  differentiation  medium,  respectively. 
Expression of myogenin and p21 was initially detected in 
mononucleated  cells,  and  all  multinucleated  myotubes 
were myogenin÷/p21 ÷. Collectively, these results indicate 
that myocytes withdraw from the cell cycle after the onset 
of myogenin expression but preceding cell fusion. 
Figure 5.  Ordered timing of induction of myogenin, p21, MHC, and cell fusion during myogenesis. C2C12 myoblasts were maintained in 
growth medium (GM) or exposed to differentiation  medium (DM) for 1-2 d and then double stained for the indicated proteins. The fre- 
quency of each observed phenotype is expressed as percentage of the total number of cells analyzed at each time point. Cells negative 
for the two markers analyzed are not plotted. Representative fields of cells exposed to DM for 2 d are shown. (A) myogenin/p21 double 
staining. The frequency of myogenin-/p21- cells and the total number of cells analyzed in GM, DM (1 d), and DM (2 d) were 99% (n = 
203), 77% (n = 430), and 49% (n = 461), respectively. Top and middle panels, immunofluorescence;  bottom, Hoechst 33258 staining. 
Note the presence of myogenin÷/p21 -  cells (arrows) and myogenin+/p21 ÷ cells. (B) MHC/p21  double staining.  The frequency of 
MHC-/p21- cells and the total number of cells analyzed in GM, DM (1 d), and DM (2 d) were 99% (n = 204), 83% (n = 453), and 
60% (n = 406), respectively. Top panel, p21 (red) and MHC (green) immunostaining; bottom, Hoechst 33258 staining. 
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cle withdrawal and phenotypic differentiation, cells were 
double stained for p21 and MHC (Fig. 5 B). Postmitotic 
undifferentiated cells (MHC-/p21 ÷) and postmitotic dif- 
ferentiated cells (MHC+/p21 ÷) expressing different levels 
of MHC were detected in differentiating cultures. How- 
ever, differentiated mitotic cells (MHC+/p21 -) were not 
observed, suggesting that induction of the contractile phe- 
notype only occurs  in  postmitotic  myocytes. Consistent 
with this hypothesis, the relative frequency of MHC  ÷ cells 
among the population of p21 ÷ cells increased from 74 to 
95%  at days  1 and 2 in differentiation medium, respec- 
tively. Moreover, MHC expression was  first detected in 
mononucleated cells,  and  all  myotubes that  occurred at 
the later time points were MHC÷/p21 +. As shown in Table 
I, these double immunostaining experiments revealed that 
myogenin  ÷ myocytes occurred at the highest frequencies 
in differentiating cultures, followed by p21 ÷ and MHC ÷ 
cells, in agreement with results from the immunoblot anal- 
yses (Fig. 4). Syncytial nuclei, an index of cell fusion, oc- 
curred at the lowest frequency (Table I). These observa- 
tions  demonstrate  that  skeletal  myogenesis  is  a  highly 
ordered process within a given cell. After the onset of ter- 
minal  differentiation,  as  indicated  by  the  expression  of 
myogenin, a myoblast withdraws from the cell cycle, then 
phenotypically differentiates, and finally, fuses to form a 
syncytial myotube. 
Discussion 
This  study  demonstrates  that  skeletal  myogenesis  is  a 
highly ordered process and elucidates the temporal rela- 
tionships among the events that govern the transition from 
the proliferative myoblast to the terminally differentiated 
myocyte. Whereas the expression of myogenin is not suffi- 
cient for cell cycle exit, subsequent  induction of p21  in 
mononucleated myogenin  + myoblasts correlates both with 
the establishment and the maintenance of the postmitotic 
state. Later during myogenesis, postmitotic (p21-positive) 
myoblasts activate the expression of contractile proteins 
and then fuse into multinucleated myotubes. 
Myogenin Expression and Cell Cycle Withdrawal Are 
Separable Events during Myogenesis 
Our initial interest was  to determine the temporal rela- 
Table L Number of Syncytial Nuclei and Cells Positive  for 
Myogenin, p21, and MHC in Cultures of Undifferentiated and 
Differentiating C2C12 Myocytes 
Differentiation Medium 
Growth medium  1 d  2 d 
Myogenin  0% (n =  203)  22% (n =  430)  51% (n =  461) 
p21  1% (n =  407)  15% (n =  883)  41% (n =  867) 
MHC  0% (n =  204)  12% (n =  453)  40% (n =  406) 
Syncytial nuclei  0% (n =  204)  3% (n =  453)  23% (n =  406) 
The frequency of each marker was calculated from the double immunoflurescence  ex- 
periments of Fig. 5. C2C12 myoblasts were maintained in growth medium or exposed 
to differentition medium for 1-2 d. To determine the frequency of syncytial nuclei, an 
index of cell fusion, the number of nuclei contained within multinucleated MHC  ÷ myo- 
tubes was expressed relative to the total number of nuclei in the corresponding micro- 
scope field. 
tionship between myogenin expression and cell cycle with- 
drawal during skeletal myogenesis. While MyoD and Myf-5 
are thought to be involved in myoblast determination, myo- 
genin is an early marker for the entry of myoblasts into the 
terminal differentiation pathway (16, 38, 45, 47). Based on 
immunolocalization  experiments,  it  has  been  suggested 
that myogenin expression only occurs in postmitotic myo- 
cytes (6, 38, 49). Consistent with this notion, it has been 
previously  reported  that  the  induction  of  myogenin 
mRNA either coincides with or follows that of p21 during 
C2 myoblast differentiation (22, 39). However, our immu- 
nodetection and immunoblot analyses show that the in- 
duction of myogenin protein precedes that of p21 (see be- 
low).  Although  we  detected  both  proteins  within  the 
nuclei of myotubes and differentiating mononucleated myo- 
cytes, a functional distinction can be made when mononu- 
cleated cells are examined with respect to their ability to 
synthesize DNA. Whereas a significant fraction of mononu- 
cleated myogenin  + cells were still capable of DNA synthesis, 
p21-expressing mononucleated myocytes failed to incor- 
porate BrdU under identical conditions. Further indica- 
tion that p21 is a bona fide marker of the postmitotic state 
of myocytes was provided by analyzing cultures of serum- 
restimulated  differentiating myocytes. In  these  cultures, 
expression of p21 was maintained in both myotubes and 
mononucleated  myocytes, and  its  expression  correlated 
with the absence of new DNA synthesis under conditions 
where p21- cells were actively replicating DNA. These re- 
suits indicate that myogenin expression, which precedes 
p21 induction, is not sufficient to promote cell cycle arrest. 
In contrast, subsequent  expression of p21  in  myogenin  + 
myoblasts correlates with the establishment as well as the 
maintenance of the postmitotic state. 
Skeletal Myogenesis Is a Highly Ordered Process 
Prior studies have suggested that cell fusion is a prerequi- 
site for the establishment and maintenance of the postmi- 
totic state (8, 9, 15, 16, 19, 26, 31, 33-35). However, other 
investigators have suggested that cell cycle withdrawal oc- 
curs before phenotypic differentiation (3-5, 10, 18, 23, 24, 
29, 30, 32, 42, 44, 50). The present study demonstrates not 
only that skeletal myogenesis is a highly ordered process, 
but that there exists a striking distinction between myoge- 
nin expression and cell cycle withdrawal and phenotypic 
differentiation. Based on these observations, we propose 
the ordered model of skeletal myogenesis schematized in 
Fig.  6.  After  growth  factor removal, proliferating myo- 
blasts asynchronously activate the expression of myogenin 
yet remain capable of synthesizing DNA.  Subsequently, 
myogenin  +  myoblasts  become  postmitotic,  mononucle- 
ated cells that  express p21.  These postmitotic cells then 
initiate  the  synthesis  of contractile proteins  and  finally 
fuse into multinucleated myotubes. Several lines  of evi- 
dence lend support for this model. First, the induction of 
myogenin preceded cell cycle arrest  and  p21  induction, 
which in turn preceded that of MHC (phenotypic differen- 
tiation); second, myogenin-/p21  +  and  MHC+/p21 -  cells 
were not observed in differentiating cultures; third, all syn- 
cytial myotubes expressed myogenin, p21, and MHC; fi- 
nally, the relative frequencies of myogenin+/p21 ÷ versus 
myogenin+/p21 -  and  MHC÷/p21 +  versus  MHC-/p21 ÷ 
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Figure 6.  Model for the myo- 
genic  differentiation  of 
C2C12  cells.  This  model 
shows the temporal relation- 
ship  between  myogenin  ex- 
pression and  the  subsequent 
myogenic  events,  but  does 
not  imply  any  causal  rela- 
tionship.  The  phenotype  as- 
sociated  with  each  of  the 
stages  of myoblasts and  dif- 
ferentiating  myocytes  is 
boxed.  Myoblasts  asynchro- 
nously  induce  myogenin  ex- 
pression  after  removal  of 
growth factors yet remain ca- 
pable  of  replicating  DNA. 
Subsequently,  myogenin  + 
myocytes withdraw from the 
cell  cycle,  then  phenotypi- 
cally differentiate, and finally 
fuse  into syncytial  myotubes 
(see text for details). 
cells progressively increased during myogenesis. Taken to- 
gether, these observations strongly suggest that differenti- 
ating C2C12 myocytes induce myogenin before the induc- 
tion of p21  and cell cycle withdrawal, and then undergo 
phenotypic differentiation and cell fusion. In this regard, it 
has been suggested previously that myoblasts exposed to 
differentiation medium enter a latent period during which 
cells remain ambivalent toward proliferation or differenti- 
ation (10, 30, 32). This latent period might correspond to 
the gap between myogenin expression and p21 expression. 
In summary, here it is shown on a cell-by-cell basis that 
in vitro myogenesis involves at least four temporally sepa- 
rable events: (1) entry of myoblasts into the differentiation 
pathway, as indicated by the induction of myogenin; (2) ir- 
reversible  cell  cycle withdrawal, as indicated by the  ex- 
pression  of p21;  (3)  phenotypic differentiation, as  indi- 
cated  by  the  induction  of  MHC;  and  (4)  cell  fusion. 
Despite a strict temporal order of expression, direct causal 
relationships  among  myogenin, p21,  and  MHC  are  un- 
likely  to  exist.  For  example,  presumptive  myoblasts  in 
myogenin(-/-)  knockout mice express  p21  mRNA and 
withdraw  from  the  cell  cycle  normally  (39).  Moreover, 
mice lacking p21 appear to develop normally (14), indicat- 
ing that p21  expression is not essential for phenotypic dif- 
ferentiation and cell cycle withdrawal. These observations 
suggest  that  functionally redundant  and/or  independent 
regulatory circuits control  the  highly ordered  myogenic 
program.  The  present study provides  a  temporal frame- 
work that will permit further dissection of the regulatory 
networks that couple myogenin expression, cell cycle with- 
drawal,  and  phenotypic  differentiation  during  skeletal 
myogenesis. 
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